Tesofensine
Also known as Tesofensine free base, NS-2330, NS2330, NS 2330
Research Goal: Analyzing the suppression of appetite and increase in resting energy expenditure through the modulation of neurotransmitter reuptake in the hypothalamus.
Route
Oral
Dose range
250 mcg – 1 mg
Frequency
Once per day
Cycle length
12–24 weeks
Overview
Research Goal: Analyzing the suppression of appetite and increase in resting energy expenditure through the modulation of neurotransmitter reuptake in the hypothalamus.
Preparation: Typically administered as an oral capsule or tablet. No reconstitution or injection required.
Studied benefits
- A potent triple monoamine reuptake inhibitor (acting on dopamine, serotonin, and noradrenaline)
- While not a peptide, it is widely researched for its significant weight loss effects, driven by intense appetite suppression and an increase in resting energy expenditure
Reported side effects
- Common side effects include dry mouth, insomnia, increased heart rate, and potential elevations in blood pressure
- It may also lead to gastrointestinal discomfort or transient mood changes
Protocol
Dosing Schedule (Oral)
Educational reference only. Not medical advice. Research compounds are not approved for human use. Full disclaimer.
Context
Lifestyle considerations
Maintain a high-protein, balanced diet to safeguard lean muscle mass while this triple monoamine reuptake inhibitor works to significantly suppress appetite and increase resting energy expenditure. Incorporate regular physical activity to support cardiovascular health and manage potential shifts in heart rate or blood pressure, which are common with norepinephrine-active compounds. Ensure 7–9 hours of quality sleep to support neural recovery and mood stabilization. Maintain optimal hydration and monitor for dry mouth or sleep disturbances, adjusting the timing of administration to early morning to minimize interference with the body’s circadian rhythm.
Evidence
Research summaries
Effect of tesofensine on bodyweight loss, body composition, and safety in obese patients
Findings: Drives 9.2-10.6% total weight loss (0.5-1.0 mg doses) versus 2% placebo over 24 weeks on calorie restriction, with 6.7 kg fat loss and cardiometabolic gains.
Across 203 obese adults (BMI 30-40 kg/m²), tesofensine scaled weight reductions dose-dependently, halving fat mass while safeguarding muscle, shrinking waists, and optimizing triglycerides/insulin. Heart rate rose modestly without dropout spikes (21% overall), evidencing a potency-safety profile eclipsing approved agents and validating central monoamine modulation for sustained obesity intervention.
Read the study ↗Weight loss produced by tesofensine in patients with obesity
Findings: Nets ~4% placebo-subtracted loss in 14 weeks sans lifestyle changes, mirroring sibutramine efficacy minus hypertension risks.
Early human data pinpointed appetite suppression as the core driver, with metabolic uplifts suggesting repurposing potential from Parkinson's origins—laying groundwork for tesofensine's obesity pivot through balanced neurotransmitter enhancement.
Read the study ↗Tesofensine induces appetite suppression and weight loss with superior effects in obese rats
Findings: Excels in diet-induced obesity via hypothalamic GABA silencing, blocks post-serotonergic rebound, no palatability disruption.
Rodent studies revealed amplified anorexigenic potency in obese states (higher metabolic ratio), with lateral hypothalamus targeting explaining human translations—serotonergic combos extended effects, forecasting hybrid therapies for weight maintenance.
Read the study ↗Tesofensine, a novel antiobesity drug, silences GABAergic neurons in the Lateral Hypothalamus
Findings: Suppresses feeding-promoting GABA cells, augments GLP-1 loss, low stereotypy versus stimulants.
Optogenetic validation confirmed neuronal specificity, boosting obese outcomes without aversion—minimal abuse signals enhance its profile for combo regimens targeting intractable obesity circuits. Tesofensine's hypothalamic precision unleashes 9-11% losses via appetite-energy synergy, trumping peers in obese models with rebound-proof potential, despite stalled approval.
Read the study ↗More references (4)
- Tesofensine: A unique triple monamine reuptake inhibitor for obesity, 2025
- Appetite Suppression and Metabolism: The Mechanism of Tesofensine, 2024
- Phase 3 results of Tesofensine for the treatment of patients with obesity, 2023
- Tesofensine in patients with obesity: a phase 2, randomised, double-blind trial, 2008
Identification
Chemistry
- common names
- Tesofensine, Tesofensine free base, NS-2330, NS2330, NS 2330, CL-201, Tesofensin, Tesufensin
- cas
- 195875-84-4 (free base)
- molecular weight
- 328.28 Da (free base); approximately 520.40 Da (citrate salt form)
- source
- Synthetic; not naturally occurring in biological systems
- biosynthesis
- Nonribosomal small-molecule synthesis via organic chemistry methodologies
Keep exploring
Related peptides
5-Amino-1MQ
5-amino-1-methylquinolinium · NNMTi
- Route
- Subcutaneous
- Dose
- 2.5 mg – 5 mg
- Cycle
- 10–20 days (based on a single 50 mg vial)
Adamax
- Route
- Subcutaneous
- Dose
- 100 mcg – 300 mcg
- Cycle
- 8–12 weeks
Adipotide (FTPP)
FTPP · Adipotide
- Route
- Subcutaneous
- Dose
- 5 mcg – 20 mcg
- Cycle
- 21–28 days; monitoring of renal markers is standard
AICAR
Acadesine · AICA-Riboside
- Route
- Subcutaneous
- Dose
- 1 mg – 3 mg
- Cycle
- 8–12 weeks